José Zarza - Academia.edu (original) (raw)
Related Authors
Università Cattolica del Sacro Cuore (Catholic University of the Sacred Heart)
Uploads
Papers by José Zarza
Medicina Clínica
1. Med Clin (Barc). 2010 Sep 4;135(7):336-7. Epub 2009 Jul 31. [Autoimmune hemolytic anemia relat... more 1. Med Clin (Barc). 2010 Sep 4;135(7):336-7. Epub 2009 Jul 31. [Autoimmune hemolytic anemia related to human parvovirus B19 infection]. [Article in Spanish]. Zarza J, Centurión ME, Armoa A, Acosta T. PMID: 19647273 [PubMed - indexed for MEDLINE]. Publication Types: ...
Piel, 2011
... GlivecTM) para la LMC ya que la mayorıa de los pacientes presentan respuesta hematoló gica co... more ... GlivecTM) para la LMC ya que la mayorıa de los pacientes presentan respuesta hematoló gica completa al tratamiento con baja toxicidad lo que mejora su supervivencia y calidad de vida. ... 1990;75:1468. 6. Nair C, Chopra H, Shinde S, Barbhaya S, Kumar A, Dhond S, et al. ...
Medicina Clínica, 2010
... Además, lo tendrá accesible para siempre desde su cuenta de usuario. Suscríbase a la revista.... more ... Además, lo tendrá accesible para siempre desde su cuenta de usuario. Suscríbase a la revista. Acceda a todos los artículos de la revista "Medicina Clínica" sin limitaciones. Zarza, José a ; Centurión, María Élida a ; Armoa, Alba a ; Acosta, Tita a. ...
Blood, 2002
The 2C9*3 and 2C9*2 polymorphisms of cytochrome P-450 CYP2C9 are associated with hypersensitivity... more The 2C9*3 and 2C9*2 polymorphisms of cytochrome P-450 CYP2C9 are associated with hypersensitivity to warfarin and bleeding. The effect of these polymorphisms on sensitivity to acenocoumarol is unknown. Three groups of patients, with low, medium, or high acenocoumarol-dose requirements, were studied. Age influenced the acenocoumarol sensitivity. Bearing the 2C9*3 allele was associated with the need for a lower acenocoumarol dose (odds ratio [OR], 6.02; 95% confidence interval [CI], 1.50-24.18); 80% of carriers of the 2C9*3 allele required a low dose. The 2C9*2 allele was associated with a lower acenocoumarol-dose requirement (OR, 2.70; 95% CI, 1.11-6.58) because of a reduced risk of the need for a high acenocoumarol dose (4.8% of the patients in the high-dose group carried the 2C9*2 allele versus 34.1% and 30.2%, respectively, in the medium-dose and low-dose groups). Therefore, carriers of 2C9*3 may need a low initial loading dose of acenocoumarol. Because acenocoumarol sensitivity with the 2C9*2 variant does not seem to be clinically relevant, the drug could be an alternative to warfarin in 2C9*2 carriers.
Revista Brasileira de Hematologia e Hemoterapia, 2011
... Raul Gabús I ; Sebastian Galeano I ; Carmino Antonio de Souza II ; Scott Howard III ; Jorge H... more ... Raul Gabús I ; Sebastian Galeano I ; Carmino Antonio de Souza II ; Scott Howard III ; Jorge Horacio Millone IV ; Mario Luis Tejerina Del ... Corresponding author: Raul Gabús Hematology Service of the Hospital Maciel, Ministry of Public Health 25 de mayo 174 11.000, Montevideo ...
Medicina Clínica
1. Med Clin (Barc). 2010 Sep 4;135(7):336-7. Epub 2009 Jul 31. [Autoimmune hemolytic anemia relat... more 1. Med Clin (Barc). 2010 Sep 4;135(7):336-7. Epub 2009 Jul 31. [Autoimmune hemolytic anemia related to human parvovirus B19 infection]. [Article in Spanish]. Zarza J, Centurión ME, Armoa A, Acosta T. PMID: 19647273 [PubMed - indexed for MEDLINE]. Publication Types: ...
Piel, 2011
... GlivecTM) para la LMC ya que la mayorıa de los pacientes presentan respuesta hematoló gica co... more ... GlivecTM) para la LMC ya que la mayorıa de los pacientes presentan respuesta hematoló gica completa al tratamiento con baja toxicidad lo que mejora su supervivencia y calidad de vida. ... 1990;75:1468. 6. Nair C, Chopra H, Shinde S, Barbhaya S, Kumar A, Dhond S, et al. ...
Medicina Clínica, 2010
... Además, lo tendrá accesible para siempre desde su cuenta de usuario. Suscríbase a la revista.... more ... Además, lo tendrá accesible para siempre desde su cuenta de usuario. Suscríbase a la revista. Acceda a todos los artículos de la revista "Medicina Clínica" sin limitaciones. Zarza, José a ; Centurión, María Élida a ; Armoa, Alba a ; Acosta, Tita a. ...
Blood, 2002
The 2C9*3 and 2C9*2 polymorphisms of cytochrome P-450 CYP2C9 are associated with hypersensitivity... more The 2C9*3 and 2C9*2 polymorphisms of cytochrome P-450 CYP2C9 are associated with hypersensitivity to warfarin and bleeding. The effect of these polymorphisms on sensitivity to acenocoumarol is unknown. Three groups of patients, with low, medium, or high acenocoumarol-dose requirements, were studied. Age influenced the acenocoumarol sensitivity. Bearing the 2C9*3 allele was associated with the need for a lower acenocoumarol dose (odds ratio [OR], 6.02; 95% confidence interval [CI], 1.50-24.18); 80% of carriers of the 2C9*3 allele required a low dose. The 2C9*2 allele was associated with a lower acenocoumarol-dose requirement (OR, 2.70; 95% CI, 1.11-6.58) because of a reduced risk of the need for a high acenocoumarol dose (4.8% of the patients in the high-dose group carried the 2C9*2 allele versus 34.1% and 30.2%, respectively, in the medium-dose and low-dose groups). Therefore, carriers of 2C9*3 may need a low initial loading dose of acenocoumarol. Because acenocoumarol sensitivity with the 2C9*2 variant does not seem to be clinically relevant, the drug could be an alternative to warfarin in 2C9*2 carriers.
Revista Brasileira de Hematologia e Hemoterapia, 2011
... Raul Gabús I ; Sebastian Galeano I ; Carmino Antonio de Souza II ; Scott Howard III ; Jorge H... more ... Raul Gabús I ; Sebastian Galeano I ; Carmino Antonio de Souza II ; Scott Howard III ; Jorge Horacio Millone IV ; Mario Luis Tejerina Del ... Corresponding author: Raul Gabús Hematology Service of the Hospital Maciel, Ministry of Public Health 25 de mayo 174 11.000, Montevideo ...